GeoVax reported a smaller-than-expected Q2 GAAP loss of $0.97 per share, beating estimates by $1.18.
GeoVax posted a Q2 GAAP loss of $0.97 per share, narrower than expected and improving by $1.18 from consensus estimates. The company attributed the result to increased government contract revenue.
For the three- and six-month periods ending June 30, 2025, GeoVax generated $852,282 and $2,489,145, respectively, from its contract with the Biomedical Advanced Research and Development Authority. The figures reflect ongoing government-backed funding for the company’s development programs.
No immediate market reaction was disclosed in the release.